

### **About Spherix Global Insights**

Spherix is the world's leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.

### **Spherix Provides Independent Expertise in Six Areas**



**Dermatology** 



**Nephrology** 



Gastroenterology



**Neurology** 



Rheumatology



**Ophthalmology** 

This is a guide to the publications Spherix will produce in 2024. It is organized by therapeutic area, indication, and deliverable.

### **Going Beyond the Data**

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

Type of Publications		
MARKET DYNAMI/	A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.	
REALTIME DYNAMIX	A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.	
LAUNCH DYNAMI/	Published monthly, Launch Dynamix tracks a new brand's first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.	
PATIENT CHART DYNAMIX	A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmasks real patient management patterns an uncovers the "why" behind treatment decisions.	
SPECIAL TOPIX	Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.	

For a complete index of available reports, visit www.clientportal.spherixglobalinsights.com



## 2024 Dermatology Publications



Atopic Dermatitis		
REALTIME DYNAMI/	<ul><li>Atopic Dermatitis, US</li><li>Atopic Dermatitis, EU5</li></ul>	
LAUNCH DYNAMIX	<ul> <li>Lebrikizumab (Eli Lilly) in Atopic Dermatitis, US*</li> <li>Nemolizumab (Galderma) in Atopic Dermatitis, US*</li> </ul>	
PATIENT CHART DYNAMI/	<ul><li>Atopic Dermatitis, US</li><li>Atopic Dermatitis, EU5</li></ul>	
SPECIAL TOPIX	<ul> <li>Atopic Dermatitis - APP (US)</li> <li>Topical Small Molecules in Atopic Dermatitis, US</li> </ul>	

Plaque Psoriasis		
REALTIME DYNAMI/	<ul><li>Plaque Psoriasis, US</li><li>Plaque Psoriasis, EU5</li></ul>	
LAUNCH DYNAMIX	<ul> <li>Bimzelx (UCB) in Plaque Psoriasis, US</li> <li>Sotyktu (BMS) in Plaque Psoriasis, US</li> <li>Vtama (Dermavant) in Plaque Psoriasis, US</li> <li>Zoryve (Arcutis) in Plaque Psoriasis, US</li> </ul>	
PATIENT CHART DYNAMI/	New Starts + Switching in Plaque Psoriasis, US	
SPECIAL TOPIX	Pre-biologics in Plaque Psoriasis, US	

Alopecia Areata		
MARKET DYNAMI/	Alopecia Areata, US	
LAUNCH DYNAMI/	<ul> <li>Deuruxolitinib (SUN Pharma) in Alopecia Areata, US*</li> <li>Litfulo (Pfizer) in Alopecia Areata, US</li> </ul>	

Hidradenitis Suppurativa	
MARKET DYNAMI/	Hidradenitis Suppurativa, US
REALTIME DYNAMIX	Hidradenitis Suppurativa, EU5
LAUNCH DYNAMI/	<ul> <li>Bimzelx (UCB) in Hidradenitis Suppurativa, US</li> <li>Cosentyx (Novartis) in Hidradenitis Suppurativa, US</li> </ul>
PATIENT CHART DYNAMIX	Hidradenitis Suppurativa, US

	Other Dermatology
MARKET DYNAMI/	<ul><li>Prurigo Nodularis, US</li><li>Vitiligo, US</li></ul>
LAUNCH DYNAMIX	<ul> <li>Dupixent (Sanofi/Regeneron) in Prurigo Nodularis, US</li> <li>Nemolizumab (Galderma) in Prurigo Nodularis, US*</li> <li>Opzelura (Incyte) in Vitiligo, US</li> </ul>
SPECIAL TOPI/	Biologic Coordinators Across Dermatology, US

	MARKET DYNAMIX	Yearly market overview of key indication
_	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
ש	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	SPECIAL TOPIX	Current events on specific interest areas



# 2024 Gastroenterology Publications



Inflammatory Bowel Disease		
REALTIME DYNAMI/	<ul> <li>Crohn's Disease, US</li> <li>Crohn's Disease, EU5</li> <li>Ulcerative Colitis, US</li> <li>Ulcerative Colitis, EU5</li> </ul>	
LAUNCH DYNAMIX	<ul> <li>Rinvoq (AbbVie) in Crohn's Disease, US</li> <li>Skyrizi (AbbVie) in Crohn's Disease, US</li> <li>Omvoh (Eli Lilly) in Ulcerative Colitis, US</li> <li>Skyrizi (AbbVie) in Ulcerative Colitis, US*</li> <li>Tremfya (Janssen) in Ulcerative Colitis, US*</li> <li>Velsipity (Pfizer) in Ulcerative Colitis, US</li> </ul>	
PATIENT CHART DYNAMI/	<ul> <li>Inflammatory Bowel Disease New Starts, US</li> <li>Inflammatory Bowel Disease Switching, US</li> <li>Inflammatory Bowel Disease New Starts, EU</li> </ul>	

Metabolic Dysfunction-associated Steatotic Liver Disease / Metabolic Dysfunction-associated Steatohepatitis		
MARKET DYNAMI/	• MASLD/MASH, US	
LAUNCH DYNAMIX	Rezdiffra (Madrigal) in MASLD/MASH	
PATIENT CHART DYNAMI/	• MASLD/MASH, US	

General Gastroenterology	
MARKET DYNAMI/	Irritable Bowel Syndrome - Constipation, US
LAUNCH DYNAMI/	Rebyota (Ferring) and Vowst (Seres) in Clostridium Difficile Infection, US

Eosinophilic Esophagitis	
MARKET DYNAMI/	Eosinophilic Esophagitis, US
LAUNCH DYNAMIX	Eohilia (Takeda) in Eosinophilic Esophagitis
PATIENT CHART DYNAMI/	Eosinophilic Esophagitis, US

	MARKET DYNAMIX	Yearly market overview of key indication
	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
'	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	SPECIAL TOPIX	Current events on specific interest areas



## 2024 Rheumatology Publications



# Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis

REALTIME DYNAMI/	<ul> <li>Ankylosing Spondylitis &amp; Non-Radiographic Axia Spondyloarthritis, US</li> <li>Ankylosing Spondylitis &amp; Non-Radiographic Axia Spondyloarthritis, EU5</li> </ul>	
LAUNCH	Bimzelx (UCB) in Ankylosing Spondylitis & Non-	
DYNAMIX	Radiographic Axial Spondyloarthritis, US*	

Psoriatic Arthritis	
REALTIME DYNAMI/	<ul><li> Psoriatic Arthritis, US</li><li> Psoriatic Arthritis, EU5</li></ul>
LAUNCH DYNAMIX	Bimzelx (UCB) in Psoriatic Arthritis, US*
PATIENT CHART DYNAMI/	Triggers and Drivers in Psoriatic Arthritis     Switching, US

Lupus	
REALTIME DYNAMI/	<ul> <li>Lupus Nephritis, US</li> <li>Systemic Lupus Erythematosus, US</li> <li>Systemic Lupus Erythematosus, EU5</li> </ul>
PATIENT CHART DYNAMIX	<ul><li>Lupus Nephritis, US</li><li>Systemic Lupus Erythematosus, US</li><li>Systemic Lupus Erythematosus, EU5</li></ul>

	General Rheumatology
MARKET DYNAMI/	<ul> <li>ANCA-Associated Vasculitis</li> <li>Cutaneous Lupus Erythematosus</li> <li>Dermatomyositis, US</li> <li>Giant Cell Arteritis, US</li> <li>Polymyalgia Rheumatica, US</li> <li>Sjogren's Syndrome</li> <li>Systemic Sclerosis, US</li> <li>Systemic Sclerosis, EU</li> </ul>
REALTIME DYNAMIX	Rheumatoid Arthritis, US
LAUNCH DYNAMI/	Kevzara (Sanofi/Regeneron) in Polymyalgia Rheumatica, US
SPECIAL TOPIX	American College of Rheumatology (ACR)     Convergence Feedback, US

MARKET DYNAMIX Yearly market overview of key indication

REALTIME DYNAMIX Quarterly (US) or semi-annual (EU5) indication updates

LAUNCH DYNAMIX Monthly benchmark of newly launched products

PATIENT CHART DYNAMIX Yearly review of large-scale patient chart audits

SPECIAL TOPIX Current events on specific interest areas

# 2024 Nephrology Publications



Kidney Disease	
MARKET DYNAMI/	<ul> <li>Autosomal Dominant Polycystic Kidney Disease, US</li> <li>Chronic Kidney Disease - Cardiorenal, US</li> <li>End-Stage Kidney Disease Modalities (Dialysis and Transplant), US</li> </ul>
REALTIME DYNAMIX	<ul> <li>Chronic Kidney Disease/Diabetic Kidney Disease, US</li> <li>Dialysis, US</li> </ul>
PATIENT CHART DYNAMI/	<ul> <li>Chronic Kidney Disease, Non-Dialysis, US</li> <li>Chronic Kidney Disease, Non-Dialysis, PCP, US</li> <li>Dialysis, US</li> </ul>
SPECIAL TOPIX	<ul><li>ASN Kidney Week Conference, US</li><li>Buy and Bill in Nephrology Practices</li></ul>

Glomerular Diseases	
MARKET DYNAMI/	<ul> <li>Complement Disorders, US</li> <li>Focal Segmental Glomerulosclerosis, US</li> <li>Membranous Nephropathy, US</li> <li>Rare Glomerular Diseases, Japan</li> </ul>
REALTIME DYNAMIX	• IgA Nephropathy, US
LAUNCH DYNAMI/	Filspari (Travere) in IgA Nephropathy, US
PATIENT CHART DYNAMI/	<ul> <li>Complement 3 Glomerulopathy, EU5</li> <li>IgA Nephropathy, US</li> <li>IgA Nephropathy, EU5</li> </ul>

Bone and Mineral Metabolism	
LAUNCH	<ul> <li>Xphozah (Ardelyx) in Hyperphosphatemia, US</li> <li>Xphozah (Ardelyx) in Hyperphosphatemia, Renal</li></ul>
DYNAMI/	Dietitians, US

	Lupus
REALTIME DYNAMI/	• Lupus Nephritis, US
PATIENT CHART DYNAMIX	• Lupus Nephritis, US

Renal Anemia	
REALTIME DYNAMI/	Renal Anemia, EU5
LAUNCH DYNAMIX	<ul><li>Jesduvroq (GSK) in Renal Anemia, US</li><li>Vadadustat (Akebia) in Renal Anemia, US</li></ul>

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
SPECIAL TOPIX	Current events on specific interest areas



## 2024 Neurology Publications



Generalized Myasthenia Gravis		
MARKET DYNAMI/	Generalized Myasthenia Gravis, US	
REALTIME DYNAMI/	Generalized Myasthenia Gravis, EU5	
LAUNCH DYNAMI/	<ul> <li>SC Vyvgart Hytrulo (Argenx), Rystiggo (UCB) and Zilucoplan (UCB) in Generalized Myasthenia Gravis, US</li> </ul>	
PATIENT CHART DYNAMIX	General Myasthenia Gravis, US	


Migraine	
REALTIME DYNAMI/	Migraine, US
LAUNCH DYNAMIX	Zavzpret (Pfizer) in Acute Migraine, US

	Alzheimer's Disease
MARKET DYNAMI/	Alzheimer's Disease, US
REALTIME DYNAMIX	Alzheimer's Disease, EU5*
LAUNCH DYNAMI/	<ul> <li>Donanemab (Lilly) in Alzheimer's Disease, US*</li> <li>Leqembi (Eisai/Biogen)in Alzheimer's Disease, US</li> </ul>
PATIENT CHART DYNAMIX	Alzheimer's Disease, US
SPECIAL TOPI/	<ul> <li>Alzheimer's Disease: Symptomatics, US</li> <li>Disruptive Events in Alzheimer's and ALS, US</li> </ul>

Multiple Sclerosis		
REALTIME DYNAMI/	<ul><li>Multiple Sclerosis, US</li><li>Multiple Sclerosis, Canada</li></ul>	
LAUNCH DYNAMIX	• SC Ocrelizumab (Genentech) in Multiple Sclerosis*	

### **General Neurology & Neurodegeneration**

MARKET DYNAMI/	<ul> <li>Amyotrophic Lateral Sclerosis, US</li> <li>Chronic Inflammatory Demyelinating Polyneuropathy, US</li> <li>Epilepsy, US</li> <li>Huntington's Disease, US</li> <li>Parkinson's Disease, US</li> </ul>
LAUNCH DYNAMIX	Ultomiris (Alexion) in NMOSD, US
SPECIAL TOPI/	Evolving Therapies in Parkinson's Disease, US





## 2024 Ophthalmology Publications



Neovascular Age-Related Macular Degeneration	
REALTIME DYNAMI/	<ul> <li>Neovascular Age-Related Macular Degeneration, US</li> <li>Neovascular Age-Related Macular Degeneration, EU5*</li> </ul>
LAUNCH DYNAMIX	<ul> <li>Eylea HD (Regeneron/Bayer) in Neovascular Age- Related Macular Degeneration <u>and</u> Diabetic Macular Edema, US</li> </ul>
PATIENT CHART DYNAMI/	Neovascular Age-Related Macular Degeneration, US

Other Ophthalmology	
MARKET DYNAMI/	<ul> <li>Diabetic Retinopathy, US</li> <li>Geographic Atrophy, US</li> <li>Thyroid Eye Disease, US</li> </ul>
LAUNCH DYNAMIX	Syfovre (Apellis) and Izervay (Iveric Bio) in Geographic Atrophy, US
SPECIAL TOPI/	Gene Therapies in Retina, US

Diabetic Macular Edema	
REALTIME DYNAMI/	Diabetic Macular Edema, US
PATIENT CHART DYNAMIX	Diabetic Macular Edema, US



## Visit The Spherix Portal



